Infants Too Young for MMR Vaccine Left Vulnerable as Measles Outbreaks Expand

In the labor and delivery unit at Prisma Health Greer Memorial Hospital in South Carolina, new parents in early 2026 received an alert that no one expects in a country that eliminated measles 26 years ago: their newborns may have been exposed to the virus [1]. The exposure event — in a maternity ward, among babies only hours or days old — crystallized a question that epidemiologists, pediatricians, and parents across the country are now confronting: what happens to the children who cannot yet protect themselves?

As of April 9, 2026, the CDC has confirmed 1,714 measles cases in the United States for the year, spread across 33 jurisdictions, with 94% of those cases linked to active outbreaks [2]. Combined with the 2,287 cases recorded in 2025 — the worst year for measles in the U.S. since 1991 — the cumulative toll of the current wave has reached approximately 4,000 cases in 15 months [3]. The country's measles elimination status, maintained since 2000, is now in jeopardy [4].

Source: CDC

Data as of Apr 9, 2026CSV

At the center of this crisis are infants. Children under 12 months cannot receive the standard MMR (measles, mumps, rubella) vaccine. Their only shield is a combination of maternal antibodies — transferred in the womb and diminishing over the first months of life — and the vaccination status of everyone around them. Both of those defenses are weakening.

The Toll on the Youngest

Measles is not an equal-opportunity illness. Its severity varies dramatically by age, and infants bear the worst of it.

Data from the current outbreak wave show that infants under 12 months who contract measles face a hospitalization rate of approximately 65% [5]. That figure dwarfs the 21% hospitalization rate observed among all children under five and the 11% overall rate across all age groups in the 2025 outbreak data [5]. Among the most severe outcomes, 34 patients required ICU-level care for an average of 8.7 days [5].

In South Carolina's Spartanburg County outbreak — the largest single-state outbreak since elimination — 253 of 997 confirmed cases as of early April were among children aged four and younger [1]. State officials declined to provide a more granular age breakdown, citing patient confidentiality [1]. Of the 920 cases reported through late March with demographic data, 243 were under five, 583 were school-aged children (5-17), and 78 were adults [6].

Source: SC DPH

Data as of Mar 28, 2026CSV

For comparison, in the pre-vaccine era of the 1950s, an estimated 48,000 Americans were hospitalized annually for measles, with roughly 150,000 experiencing respiratory complications and 4,000 developing encephalitis (brain swelling) each year [7]. An average of 450 measles-related deaths occurred annually from 1956 to 1960, a case-fatality rate of approximately 1 per 1,000 reported cases [7]. By the time 95% of Americans had contracted measles before age 15, the disease was so ubiquitous that nearly all mothers had natural immunity to pass on to their infants [7].

That dynamic has shifted. Today's mothers, most of whom were vaccinated rather than naturally infected, transfer lower levels of measles antibodies to their newborns. Vaccine-induced immunity generates a protective antibody response, but studies have shown that the quantity of maternal IgG antibodies transferred to the fetus — a process that accelerates in the final four to six weeks of gestation — tends to be lower for vaccinated women than for those who had natural measles infection [8]. This means today's infants may lose passive maternal protection earlier, potentially by three to four months of age rather than the six months or more that was typical in the pre-vaccine era.

The Vaccination Gap and Early-Dose Dilemma

The standard U.S. immunization schedule calls for the first MMR dose at 12–15 months, with a second dose at 4–6 years. Both the CDC and the American Academy of Pediatrics (AAP) permit an early dose for infants aged 6–11 months in two circumstances: international travel and outbreak exposure [9]. During the South Carolina outbreak, state health officials approved early vaccination for infants as young as six months, and almost 1,200 early MMR doses were administered statewide to infants in that age group in January 2026 alone [6].

But the early-dose option comes with caveats. A dose given before 12 months does not "count" toward the standard two-dose series; the child will still need two additional doses after their first birthday for full protection [9]. And public health authorities have been cautious about broadening early-dose recommendations beyond defined outbreak zones, even as the number of affected jurisdictions climbs.

Several factors contribute to this caution. The immunological response to the MMR vaccine at 6 months is weaker than at 12 months, because residual maternal antibodies can interfere with the vaccine's effectiveness [8]. There is also a regulatory framework built around the standard schedule: vaccine adverse-event reporting, liability protections under the National Childhood Vaccine Injury Act, and insurance coverage norms are all calibrated to the 12-month-and-older recommendation [9]. Deviating from that schedule at scale would require updated guidance from the Advisory Committee on Immunization Practices (ACIP), coordination among state health departments, and potentially new emergency-use frameworks.

For the roughly 3.6 million infants born in the U.S. each year, the result is a population-level vulnerability window. Every baby spends at least six months — and typically 12 — relying entirely on the immunity of others.

Importation, Hesitancy, and the Drivers of Infant Exposure

The public narrative around America's measles resurgence has centered on vaccine hesitancy — the growing refusal or delay of routine childhood immunizations. The data broadly supports this framing, but with important nuance.

Of the measles cases reported in the 2025 outbreak cycle, over 90% occurred in individuals who were unvaccinated or whose vaccination status was unknown [3]. In the South Carolina outbreak specifically, 840 of 920 cases with available data were in unvaccinated individuals, with only 24 in people confirmed to be fully vaccinated [6]. Nationally, kindergarten MMR vaccination coverage has fallen from 95.2% in the 2019-2020 school year to 92.5% in 2024-2025 — a decline that has pushed 39 states below the 95% herd immunity threshold [2][10].

Source: CDC

Data as of Jan 1, 2025CSV

Importation, however, remains the spark that ignites domestic outbreaks. Among 2025 cases with available source data, 48 (6%) were internationally imported, and 92% of those imported cases occurred among U.S. residents returning from travel abroad [5]. The pattern is consistent with previous years: a traveler brings the virus home, and it spreads rapidly through under-vaccinated communities that would have contained it a decade ago.

The distinction matters for infants. An imported case is a stochastic event — difficult to predict and harder to prevent. But the size and duration of the outbreak that follows depends almost entirely on local vaccination rates. In a community where 95% or more of the population is immunized, an imported case typically produces fewer than one secondary infection. In Spartanburg County, where some schools reported that as few as 21% of children had received all required vaccines, a single introduction led to nearly 1,000 cases over several months [1][11].

The Exemption Map and Where Outbreaks Concentrate

Forty-four U.S. states allow religious exemptions from school vaccination requirements, and 17 allow broader philosophical exemptions [12]. The geographic pattern of outbreaks tracks closely with exemption availability: Idaho, Texas, Utah, and Florida — all of which allow both religious and philosophical exemptions — have seen measurable clusters [12].

Exemption rates have climbed in more than half of U.S. counties since the start of the COVID-19 pandemic [10]. A CNN analysis of county-level data found that "patches of low vaccination in the US are becoming bigger, riskier holes," with previously isolated pockets of under-vaccination expanding and beginning to overlap [10].

The question of whether outbreaks remain confined to communities with active exemption cultures or whether they spill into surrounding well-vaccinated populations is central to the policy debate. The South Carolina data suggests both dynamics are at play. The outbreak originated in the Spartanburg County Upstate region, where religious and philosophical objections to vaccination are prevalent [11]. But as the outbreak grew, exposure events occurred in hospitals, a BMW manufacturing plant, and retail locations — settings where unvaccinated and vaccinated populations mix [1][13]. Linked cases were subsequently reported in New Mexico, Oklahoma, Kansas, and several other states [3].

In South Carolina, Democratic legislators introduced a bill to eliminate religious vaccine exemptions in response to the outbreak, while opponents characterized the proposal as government overreach into parental rights [14]. "Parental choice is a big buzzword in a lot of the Southern states," said Dr. Martha Edwards, president of the South Carolina chapter of the AAP [1]. The legislation has not advanced.

Compounded Vulnerability: Which Infants Face the Greatest Risk

Not all infants face equal risk from measles exposure. Several populations face compounded vulnerability:

Premature infants receive fewer maternal antibodies because the active transfer of IgG across the placenta accelerates in the final weeks of gestation [8]. A baby born at 28 weeks may have substantially lower passive immunity than one born at term.

Immunocompromised infants — those with congenital immune deficiencies, HIV, or undergoing cancer treatment — cannot receive live vaccines like the MMR at any age and depend entirely on herd immunity for protection [15]. The WHO identifies immunocompromised persons as among the most vulnerable to severe measles outcomes [15].

Infants in rural or low-income areas face practical barriers to both vaccination and treatment. Some rural counties that experienced outbreaks in 2025 had healthcare provider shortages that delayed diagnoses and allowed wider transmission [16]. The overlap between healthcare access deserts and low-vaccination areas is not accidental — both reflect the same underlying patterns of resource scarcity.

The geographic overlap between these vulnerable populations and active outbreak zones has not been systematically mapped at the federal level. But the Spartanburg County outbreak offers a case study: the region includes both affluent communities with ideological objections to vaccination and lower-income neighborhoods where access to pediatric care is limited [11].

The Maternal Immunization Gap

One approach to protecting infants that has received surprisingly little policy attention in the U.S. is maternal immunization — ensuring that women of childbearing age have strong measles immunity before pregnancy, so that higher levels of protective antibodies are transferred to the fetus.

The American College of Obstetricians and Gynecologists (ACOG) recommends that all women of childbearing age who lack evidence of measles immunity receive the MMR vaccine at least one month before becoming pregnant [8]. The MMR vaccine is contraindicated during pregnancy because it is a live vaccine, but postpartum vaccination — ideally before hospital discharge — is recommended for non-immune mothers [8].

Despite this guidance, there is no organized U.S. program to screen women of reproductive age for measles immunity or to promote pre-conception MMR vaccination. In contrast, several countries have implemented targeted booster campaigns for women of childbearing age as part of their measles elimination strategies [15]. The infrastructure for maternal immunization exists — flu and Tdap vaccines are routinely administered during pregnancy — but extending a similar framework to pre-conception MMR boosters has not been formally recommended by ACIP.

The gap is partly conceptual. Measles immunization policy in the U.S. has historically focused on children, with the assumption that childhood vaccination produces lifelong immunity. But with evidence that vaccine-induced maternal antibody transfer is lower than that from natural infection, and with outbreaks now recurring in communities where some mothers themselves were never vaccinated, the case for a more active maternal strategy is growing.

The Economic Calculus

The 2025 measles resurgence carried an estimated economic burden of $244.2 million across 2,280 cases — an average cost of approximately $104,629 per case [17]. Outbreak response activities, including contact tracing, laboratory testing, and post-exposure vaccination, accounted for 65.2% of total costs. Productivity losses from missed work and school represented 32.1%, while direct medical expenses — including an estimated 554 hospitalizations — made up just 3.0% [17].

Those per-case costs escalate rapidly with outbreak size. A Johns Hopkins analysis estimated average costs of approximately $43,000 per case across outbreaks since 2000, with a range from under $7,000 to more than $243,000 depending on the setting and duration [18].

The projections for continued decline are stark. If MMR vaccination coverage drops by one percentage point annually over the next five years, modeling estimates that annual cases could reach 17,232 by 2030, generating 4,085 hospitalizations, 36 deaths, and costs of $1.5 billion per year — with cumulative five-year costs of $7.8 billion [17]. Even smaller annual declines of 0.25 to 0.5 percentage points would produce "steadily increasing burdens" [17].

At what scale does federal emergency intervention become cost-justified? The current patchwork response — with local and state health departments absorbing the bulk of outbreak management costs — is already straining budgets. The National Association of County and City Health Officials (NACCHO) has called for additional federal resources, including targeted subsidies for vaccination campaigns and enhanced disease surveillance [19]. The CDC has developed outbreak simulation tools for local decision-makers but has not issued broad emergency recommendations beyond the existing guidelines [20].

What the Science Tracks

Academic research interest in measles and infant vaccination has surged in recent years, with nearly 1,970 papers published on the topic in 2023 alone, according to OpenAlex data [21]. The volume has since declined — 411 papers so far in 2026 — but the body of evidence on infant vulnerability, maternal antibody kinetics, and early-dose immunogenicity continues to expand.

Source: OpenAlex

Data as of Jan 1, 2026CSV

The CDC's Center for Forecasting and Outbreak Analytics has modeled the South Carolina outbreak under three scenarios [20]. Under Scenario A (contained), the outbreak would be limited to the currently affected community and last less than six months. Under Scenario B (regional spread, deemed most likely as of March 2026), transmission continues for at least six months across the Upstate region. Under Scenario C (multi-state expansion), the outbreak exceeds the 2025 West Texas outbreak in scale and duration, requiring substantial multi-regional public health resources [20].

Modeling within a hypothetical 15,000-person community illustrates the sensitivity of outcomes to baseline immunity: at 90% immunity, the model projects a median of 21 cases over one year; at 80%, that number jumps to 1,998; at 70%, it reaches 4,107 [20].

The Road Ahead

The United States is now in its second consecutive year of large-scale measles outbreaks — a situation that has not occurred since the early 1990s. The infants caught in this resurgence did not choose to be unvaccinated. They are, by definition, too young. Their protection depends on the decisions of the adults and communities around them: whether parents vaccinate older children, whether states tighten or loosen exemption policies, whether the federal government invests in outbreak response, and whether physicians and public health officials mount a more aggressive campaign for early-dose vaccination and maternal immunity.

"Babies become sitting ducks," said Dr. Deborah Greenhouse, a Columbia, South Carolina pediatrician. "The burden is on all of us to protect all of us" [1].

The arithmetic of herd immunity is unforgiving. At 95% vaccination coverage, measles outbreaks sputter and die. At 92.5% — where the national average now sits — they can smolder for months. And in the pockets where coverage drops to 80% or below, the virus behaves much as it did in the 1950s, when nearly every child was infected before their 15th birthday [7][10]. The difference is that in 2026, the tools to prevent that outcome exist. The question is whether they will be used.